SPR Therapeutics Raise $5M For Commercializing Pain Therapies

SPR Therapeutics, a medical device company, has raised $5 million in the initial phase of financing for the commercialization of pain therapies using its proprietary peripheral nerve stimulation technology, according to a peHUB report.   

Advertisement

SPR Therapeutics has developed devices and technologies, such as the Micropulse investigational pain therapy device, to address acute and chronic joint pain disorders. SPR’s therapies use a method of peripheral nerve stimulation to treat pain, where electrodes are positions in proximity to but not directly contacting peripheral nerves.

More Articles on Pain Management:

New Pain Management Center Opens in Virginia
Indiana State Senator Drafts Legislation to Restrict Opioid Prescriptions
Prospira PainCare Acquires National Pain Institute

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.